Apr 15 |
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
|
Apr 12 |
Eagle Pharmaceuticals receives notification of deficiency from Nasdaq
|
Apr 12 |
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
|
Mar 11 |
Eagle Pharmaceuticals announces resignation of Brian Cahill as CFO
|
Feb 29 |
Eagle Pharmaceuticals to cut 36% of workforce
|
Jan 18 |
Eagle files lawsuit in patent dispute over cancer therapy
|
Jan 18 |
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
|
Nov 29 |
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Nov 29 |
Eagle Pharmaceuticals falls after disclosing non-compliance with Nasdaq rule
|
Nov 29 |
Eagle Pharmaceuticals says Scott Tarriff has retired as CEO
|